Search Result

Results for "

vascular disorder

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Autophagy (2) Casein Kinase (1) CaSR (3) DNA/RNA Synthesis (1) Isotope-Labeled Compounds (1) LPL Receptor (1) MAPKAPK2 (MK2) (1) Neurokinin Receptor (3) NOD-like Receptor (NLR) (1) PDGFR (1) Phosphomannose Isomerase (PMI) (1) Pim (1) Reference Standards (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (8) Endocrinology (3) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: VEGFR VAP-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W726640

Peraquinsin	MAPKAPK2 (MK2)	Cardiovascular Disease Metabolic Disease
Peraquinsin is a MK2 activator. Peraquinsin can be used for the research of vascular disorder or endothelial barrier disorder. Peraquinsin also is an antihypertensive agent .

HY-N1362

Salvianolic acid B 10+ Cited Publications Lithospermic acid B	Autophagy	Cardiovascular Disease
Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.

HY-B1107

Naftidrofuryl oxalate Nafronyl oxalate salt	5-HT Receptor	Cardiovascular Disease
Naftidrofuryl oxalate (Nafronyl oxalate salt) is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.

HY-109171

Elinzanetant NT-814; BAY3427080	Neurokinin Receptor	Cardiovascular Disease Neurological Disease
Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women .

HY-157746

CTPS1-IN-1	DNA/RNA Synthesis	Inflammation/Immunology Cancer
CTPS1-IN-1 (compound R80) is a CTPS1 inhibitor. CTPS1-IN-1 has the potential to research cancer (such as promoting vascular injury or surgical recovery) and immune system diseases (such as rejection of transplanted cells and tissues, transplant-related diseases or disorders, allergies, and autoimmune diseases) .

HY-119440

Xanthinol	PDGFR	Cardiovascular Disease
Xanthinol is a vasodilator that can be used for the study of peripheral and cerebral vascular disorders .

HY-135816

CK2/PIM1-IN-1	Casein Kinase Pim	Inflammation/Immunology Cancer
CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1, with IC₅₀s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CK2/PIM1-IN-1 is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders .

HY-N1362R

Salvianolic acid B (Standard) Lithospermic acid B (Standard)	Reference Standards Autophagy	Cardiovascular Disease
Salvianolic acid B (Standard) is the analytical standard of Salvianolic acid B. This product is intended for research and analytical applications. Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.

HY-109171R

Elinzanetant (Standard) NT-814 (Standard); BAY3427080 (Standard)	Reference Standards Neurokinin Receptor	Cardiovascular Disease Neurological Disease
Elinzanetant (Standard) is the analytical standard of Elinzanetant. This product is intended for research and analytical applications. Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women .

HY-109171S

Elinzanetant-d3 NT-814-d₃; BAY3427080-d₃	Isotope-Labeled Compounds Neurokinin Receptor	Cardiovascular Disease Neurological Disease
Elinzanetant-d₃ (NT-814-d₃) is deuterium labeled Elinzanetant. Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women .

HY-146765

AMS-17	NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders, such as vascular dementia (VaD) .

HY-109106A

Upacicalcet sodium SK-1403; AJT240; PLS240	CaSR	Endocrinology
Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .

HY-109106

Upacicalcet SK-1403 free acid; AJT240 free acid; PLS240 free acid	CaSR	Endocrinology
Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .

HY-109106B

(Rac)-Upacicalcet (Rac)-SK-1403 free acid; (Rac)-AJT240 free acid; (Rac)-PLS240 free acid	CaSR	Endocrinology
(Rac)-Upacicalcet is the racemate of Upacicalcet (HY-109106). Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .

HY-138802

ML089 1 Publications Verification	Phosphomannose Isomerase (PMI)	Metabolic Disease
ML089 is a potent, selective, and orally available phosphomannose isomerase (PMI) inhibitor with an IC₅₀ of 1.3 µM. ML089 can be used for the research of congenital disorder of glycosylation Ia .

HY-148115

S1p receptor agonist 2	LPL Receptor	Inflammation/Immunology
S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the S1P1 and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders .

Cat. No.	Product Name

HY-L088

Angiogenesis-Related Compound Library	2,789 compounds
Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer). MCE offers a unique collection of 2,789 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Angiogenesis-Related Compound Library

2,789 compounds

Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).

MCE offers a unique collection of 2,789 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure